Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
ACON US​

Aclarion, Inc.(ACON US)

$1.93-0.010.26%Ext:$2.33+0.4020.71%(Market Closed · 00:00:03 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Aclarion, Inc. — Company Profile

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UQ
CEO
Brent Ness
Headquarters
Broomfield, CO, US
IPO Date
Apr 22, 2022
Employees
11
Website
www.aclarion.com

Key Metrics

Price
$2.38
Market Cap
$1.27M
Revenue (TTM)
$21.14K
Net Income (TTM)
$-2853575.00
EPS (TTM)
-1.34
P/E (TTM)
-0.16
P/B (TTM)
0.06
Dividend Yield
0.00%
ROE (TTM)
-14.52%
ROA (TTM)
-13.83%
Operating Margin
-141.29%
Beta
0.88

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.

Website
www.aclarion.com
Location
Broomfield, CO, US
Phone650-241-1741
Employees11
CEOBrent Ness
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateApr 22, 2022

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(261)

Expand
  • 4Williams Amanda M19 Aug
  • 4Gould Gregory A18 Aug
  • 4Bond Ryan17 Aug
  • 4Wesemann William17 Aug
  • 4Neal David K17 Aug
  • 4Ness Brent17 Aug
  • 10-QQ2ended 30 Jun 20266 Aug
  • S-8REGISTRATION STATEMENT9 Jul
  • 4Bond Ryan12 Jun
  • 4Sequira Amanda Mae12 Jun
  • 4Breidbart Scott12 Jun
  • 4Gould Gregory A12 Jun
  • 4Ness Brent12 Jun
  • 4Wesemann William12 Jun
  • 4Thramann Jeffrey John12 Jun
  • 4Neal David K12 Jun
  • 4Deitsch Stephen12 Jun
  • 8-KSubmission of Matters to a Vote of Security Holders4 Jun
  • 10-QQ1ended 31 Mar 202613 May
  • 4Breidbart Scott12 May

News

  • Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs22 Oct
  • Aclarion to Present at the 20th Annual LD Micro Main Event13 Oct
  • Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment8 Oct
  • Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment8 Oct
  • Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites29 Sep
  • Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites29 Sep
  • Aclarion, Inc. (NASDAQ:ACON) Short Interest Update28 Sep
  • Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)16 Sep
  • Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site20 Aug
  • Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site20 Aug
  • Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process12 Aug
  • Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process12 Aug
  • Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates6 Aug
  • Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology4 Aug
  • Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology4 Aug
  • Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 202629 Jul
  • Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 202629 Jul

Mentions in Filings

  • … 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of <strong>Aclarion, Inc.</strong> (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
    AUDDIA INC.Aclarion, Inc.·DEFM14A - DEFINITIVE PROXY RELATING TO MERGER·Q3 26·11 Aug
  • … 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of <strong>Aclarion, Inc.</strong> (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
    McCarthy Finney, Inc.Aclarion, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q3 26·11 Aug
  • … 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of <strong>Aclarion, Inc.</strong> (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
    McCarthy Finney, Inc.Aclarion, Inc.·DEFM14A - DEFINITIVE PROXY RELATING TO MERGER·Q3 26·11 Aug
  • … 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of <strong>Aclarion, Inc.</strong> (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
    McCarthy Finney, Inc.Aclarion, Inc.·S-4/A - FORM S-4 AMENDMENT NO. 3·Q3 26·29 Jul
  • … 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of <strong>Aclarion, Inc.</strong> (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
    McCarthy Finney, Inc.Aclarion, Inc.·S-4 - Registration statement (business combination)·Q2 26·14 May
  • … an independent consultant and an independent investor since 2002 in the software and consumer services industries. In addition to his role as a member of the Board, Mr. Wesemann has served on the board of directors of <strong>Aclarion, Inc.</strong> (NASDAQ: ACON), a medical SAAS company that listed on Nasdaq in 2022, since 2014 and has served as its Lead Independent Director since 2022. He also serves on the boards of directors of several privately-held companie …
    LIVEPERSON INCAclarion, Inc.·10-K/A - Annual report (amendment) FY 2025·FY25·30 Apr

Key Stats

Trading

Px/Chg 1D$2.38 / -2.46%
Prev Close$2.35
% of 52Wk H20.28%
Avg Volume92.81K
Beta0.88
Mkt Cap1.27M
FD Mkt Cap1.30M

Float

Shrs Out/Float533.31K / 2.04M
Short Float0.10%
Days to Cover1.00
Stock Repurchased$0.00

Current Valuation

EV-17735700.58
EV/EBITDA2.27
EV/Sales-227.73
P/B0.06
P/S16.30
FCF Yield-208.14%
ROE-14.52%
ROA-13.83%
Current Ratio19.65

Estimates

P/E-0.16
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgJun '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-0.38-0.59-0.00-0.00-0.89-0.44
Price / Sales43.8469.390.210.1590.6958.78
Price / Book Value0.411.88-0.020.010.130.06
Price / Free Cash Flow-0.46-0.81-0.00-0.00-1.00-0.47
ENTERPRISE VALUE METRICS
Enterprise Value-5.12.70.1-0.4-10.3-17.8
Enterprise Value / Sales-272.5945.021.60-9.77-559.55-840.23
Enterprise Value / EBITDA2.31-0.50-0.030.075.666.36
Enterprise Value / EBIT2.25-0.49-0.030.075.476.22

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue5.9%0.10.10.10.00.1
Gross Income123.2%-0.0-0.0-0.0-0.1-0.2
EBITDA13.1%-4.3-5.4-4.1-6.3-7.0
EBIT12.8%-4.5-5.6-4.3-6.5-7.2
Net Income9.9%-5.0-7.1-4.9-7.0-7.2
EPS (Diluted)-89.7%-120,035.00-177,396.00-79,782.00-7,480.22-13.61
BALANCE SHEET
Cash & ST Inv129.6%0.41.51.00.512.0
Total Assets64%1.92.92.52.113.7
Total Liabilities-42.4%7.60.73.21.20.8
Total Shareholder Equity—-5.72.2-0.71.012.8
CASH FLOW
Net Operating Cash Flow32.1%-2.3-4.9-3.6-5.3-7.2
Cap Ex1,111.3%-0.0-0.2-0.1-0.3-0.0
Free Cash Flow32.2%-2.3-5.2-3.8-5.6-7.2

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)1.94
Basic Shares0.53
Market Cap1.0
Diluted Shares2.13
Fully Diluted Shares Outstanding2.13
Fully Diluted Market Cap4.1
+Consolidated Debt-
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-19.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value-18.0

Related companies

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG

RadNet, Inc.

RDNT US

Sotera Health Co

SHC US

Vontier Corp

VNT US